Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Novel Approaches Target Esophageal Cancer

Page View:

    Researchers say they have discovered that esophageal cancer can be classified into three subtypes, paving the way for testing targeted treatments tailored to patients’ diseases for the first time.

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

        Their study (“Mutational Signatures in Esophageal Adenocarcinoma Reveal Etiologically Distinct Subgroups with Therapeutic Relevance”), published in Nature Geneticscould help find drugs that target specific weaknesses in each subtype of the disease, which could make treatment more effective and boost survival, according to the investigators.


Esophageal Cancer.webp

       The scientists, funded by Cancer Research U.K.U.K. and the Medical Research Council, looked at the complete genetic makeup of 129 esophageal cancers and subdivided the disease into three distinct types based on patterns detected in the D.N.A. of the cancer cells called signatures.

Related Articles:

Esophageal Cancer Linked to Specific Types of Oral Bacteria


        The first subtype they found had faults in D.N.A. repair pathways. Damage to this pathway is known to increase the risk of breast, ovarian, and prostate cancers. Patients with this subtype may benefit from poly(ADP-ribose) polymerase (PARP) inhibitors that kill cancer cells by exploiting this weakness in their ability to repair D.N.A.


       The second subtype had a higher number of mutations and more immune cells in the tumors, which suggests these patients could benefit from immunotherapy drugs already showing great promise in several cancer types, such as skin cancer.


       The final subtype had a D.N.A. signature mainly associated with cell aging. This group might benefit from drugs targeting proteins on the surface of the cancer cells that make cells divide.


       “Our study suggests we could change how we treat esophageal cancer,” said Rebecca Fitzgerald, M.D.M.D., lead researcher based at the M.R.C. Cancer Unit at the University of Cambridge. “Targeted treatments for the disease have so far not been successful, and this is mostly down to the lack of ways to determine which patients might benefit from different treatments. These new findings give us a greater understanding of the D.N.A. signatures that underpin different disease subtypes and mean we could better tailor treatment.”


       “The next step is to test this approach in a clinical trial. The trial would use a D.N.A. test to categorize patients into one of the three groups to determine the best treatments for each group and move away from a one-size-fits-all approach.”.


    According to Peter Johnson, M.D.M.D., Cancer Research U.K.’sU.K.’s chief clinician, “Being able to distinguish distinct types of esophageal cancer is a genuine discovery from this work. For the first time, we may be able to identify and test targeted treatments designed to exploit cancer’s specific weaknesses. Although survival rates from esophageal cancer have been slowly rising in the last few years, they are still far too low, and this research points the way to a completely new way of understanding and tackling the disease.”

Relevant newsRelevant news